m+Medelevator.RU
← Поиск публикаций
Nature communications · 2026

Targeting IP6 signaling to destabilize homologous recombination proteins to overcome PARP inhibitor resistance.

СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Lee Seon-Gyeong, Seo Yuri, Jeong Seula, Chung Yuheon, Kong Sukyeong, Kim Minyoung, Rhlee Joon Ho, Um Sihyeon, Mathew Bijoy P, Maiti Saikat, Kuram Malleswara Rao, Abozeid Mohamed Ahmed, Park Areum, Yoo Ji-Na, Khim Keon Woo, Son Kyuwon, Amarsanaa Enkhzul, Kim Kyunghan, Hong Sehoon, Choi Jiyeon, Park In Bae, Lee Eun A, Jeon Ji Hwan, Park Jun Hong, Han Joo Seok, Park Chan Young, Kim Seyun, Choi Jang Hyun, Hong Sung You, Seo Min-Duk, Lee Hyuk, Lee Joo-Yong, Myung Kyungjae

Аннотация

Homologous recombination (HR) is crucial for maintaining genomic integrity and is tightly regulated, yet the role of ubiquitin-dependent degradation in HR proteins remains poorly understood. Through high-throughput screening for compounds that modulate the DNA replication stress response, we identify ML367 and its derivative, UNI418. Kinase profiling and detail molecular analyses reveal that UNI418 inhibits PIKfyve and PIP5K1C, reducing inositol hexaphosphate (IP6) levels and triggering Cul4A-dependent degradation of RAD51, CtIP, and CHK1. Further analysis identifies WDR5 as a DCAF protein that facilitates Cul4A-mediated proteolysis of RAD51 and CHK1. Functionally, UNI418 suppresses HR, enhances tumor sensitivity to PARP inhibitors (PARPis), and re-sensitizes PARPi-resistant tumor cells in both in vitro and in vivo xenograft models. These findings reveal a Cul4A-WDR5-dependent proteolysis pathway regulating HR protein stability via phosphatidyl inositol signaling. This mechanism offers a promising therapeutic strategy for overcoming PARPi resistance and improving combinatorial cancer treatment strategies.

Предметные рубрики MeSH

ИП Урсолов Владлен Сергеевич

ИНН 500118482352 · ОГРНИП 314500117700049

Реквизиты и контакты